154 related articles for article (PubMed ID: 34816442)
1. Reassessing the Pediatric Dosing Recommendations for Unfractionated Heparin Using Real-World Data: A Pharmacokinetic-Pharmacodynamic Modeling Approach.
Salem AM; Niu T; Li C; Moffett BS; Ivaturi V; Gopalakrishnan M
J Clin Pharmacol; 2022 Jun; 62(6):733-746. PubMed ID: 34816442
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic Modeling Using Real-World Data to Optimize Unfractionated Heparin Dosing in Pediatric Patients on Extracorporeal Membrane Oxygenation and Evaluate Target Achievement-Clinical Outcomes Relationship.
Salem AM; Smith T; Wilkes J; Bailly DK; Heyrend C; Profsky M; Yellepeddi VK; Gopalakrishnan M
J Clin Pharmacol; 2024 Jan; 64(1):30-44. PubMed ID: 37565528
[TBL] [Abstract][Full Text] [Related]
3. Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics.
Trucco M; Lehmann CU; Mollenkopf N; Streiff MB; Takemoto CM
J Thromb Haemost; 2015 May; 13(5):788-94. PubMed ID: 25740425
[TBL] [Abstract][Full Text] [Related]
4. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
5. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
[TBL] [Abstract][Full Text] [Related]
6. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
[TBL] [Abstract][Full Text] [Related]
8. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels.
Schechter T; Finkelstein Y; Ali M; Kahr WH; Williams S; Chan AK; Deveber G; Brandão LR
J Thromb Haemost; 2012 Mar; 10(3):368-74. PubMed ID: 22244010
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.
Dingus SJ; Smith AR; Dager WE; Zochert S; Nothdurft SA; Gulseth MP
Ann Pharmacother; 2022 Dec; 56(12):1289-1298. PubMed ID: 35499336
[TBL] [Abstract][Full Text] [Related]
10. Clinical use of unfractionated heparin therapy in children: time for change?
Newall F; Ignjatovic V; Johnston L; Summerhayes R; Lane G; Cranswick N; Monagle P
Br J Haematol; 2010 Sep; 150(6):674-8. PubMed ID: 20629660
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin.
van Roessel S; Middeldorp S; Cheung YW; Zwinderman AH; de Pont AC
Neth J Med; 2014 Jul; 72(6):305-10. PubMed ID: 25319855
[TBL] [Abstract][Full Text] [Related]
12. Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients.
Al-Sallami H; Newall F; Monagle P; Ignjatovic V; Cranswick N; Duffull S
Br J Clin Pharmacol; 2016 Jul; 82(1):178-84. PubMed ID: 26972703
[TBL] [Abstract][Full Text] [Related]
13. Unfractionated heparin dosing requirements in the presence of inflammation during the first six months of life.
Heizer JW; Schardt TQ; Murphy ME; Branchford BR
Thromb Res; 2019 May; 177():17-22. PubMed ID: 30844684
[TBL] [Abstract][Full Text] [Related]
14. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
[TBL] [Abstract][Full Text] [Related]
15. Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
Dieplinger B; Egger M; Luft C; Hinterreiter F; Pernerstorfer T; Haltmayer M; Mueller T
J Vasc Surg; 2018 Aug; 68(2):400-407. PubMed ID: 29571622
[TBL] [Abstract][Full Text] [Related]
16. Concordance between Activated Partial Thromboplastin Time and Antifactor Xa Assay for Monitoring Unfractionated Heparin in Hospitalized Hyperbilirubinemic Patients.
Mahmoud L; Zullo AR; McKaig D; Berard-Collins CM
R I Med J (2013); 2016 Mar; 99(3):33-7. PubMed ID: 26929970
[TBL] [Abstract][Full Text] [Related]
17. How to use unfractionated heparin to treat neonatal thrombosis in clinical practice.
Bhatt MD; Paes BA; Chan AK
Blood Coagul Fibrinolysis; 2016 Sep; 27(6):605-14. PubMed ID: 26656898
[TBL] [Abstract][Full Text] [Related]
18. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
[TBL] [Abstract][Full Text] [Related]
19. [Monitoring of anticoagulant treatment with Unfractionated Heparin in pediatrics].
Aguirre N; Rivera C; Muñoz G; Valle P; Panes O; Zuñiga P
Andes Pediatr; 2022 Dec; 93(6):826-831. PubMed ID: 37906799
[TBL] [Abstract][Full Text] [Related]
20. Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy.
Byun JH; Jang IS; Kim JW; Koh EH
Blood Res; 2016 Sep; 51(3):171-174. PubMed ID: 27722127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
